Sava Infond d.o.o. Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Sava Infond d.o.o. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,250 shares of the medical research company’s stock, valued at approximately $2,014,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of IQV. Vanguard Group Inc. grew its position in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. FMR LLC grew its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in IQVIA by 2.5% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after acquiring an additional 59,426 shares during the last quarter. Cantillon Capital Management LLC raised its holdings in shares of IQVIA by 12.3% during the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock worth $406,018,000 after acquiring an additional 226,017 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Down 0.8 %

Shares of NYSE IQV opened at $179.91 on Thursday. The stock has a market capitalization of $31.72 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $179.12 and a 12-month high of $253.84. The stock’s fifty day simple moving average is $193.92 and its two-hundred day simple moving average is $207.10.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.